Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia

A pilot study

M. DeCastro, N. El-Khoury, L. Parton, Praveen Ballabh, E. F. LaGamma

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: As effects of glucocorticoids differ with respect to preparation, dose and duration, we hypothesized that a postnatal regimen of a low-dose, short-course betamethasone treatment had comparable efficacy and a better safety profile compared to the conventional high-dose, dexamethasone. Study Design: To test our hypothesis, we selected premature neonates with a birth weight ≤1000 g and a gestational age ≤29 weeks who were ventilated >10 postnatal days with an FiO2>0.4 and no ability to wean mechanical support for >3 consecutive days. These neonates either received twice daily dexamethasone 0.25 mg kg-1 per dose intravenously for 3 days tapered to 0.125 mg kg-1 per dose for 4 days (June 1999 to December 2000) or betamethasone 0.125 mg kg-1 per day intramuscularly once per day for 3 days (January 2001 to December 2002). Result: We found a significant reduction in FiO2 after 3 days in both glucocorticoid treatment groups. There were no significant differences between the two treatment groups in the clinical parameters including decrease in FiO2, oxygenation index, mean airway pressure and percent extubation. Duration of ventilation, number of oxygen days and length of hospital stay were comparable in the two groups. Of particular interest, the betamethasone group showed fewer adverse effects, such as poor weight gain and high blood glucose, than the dexamethasone group. Conclusion: A short course of low-dose betamethasone has comparable efficacy and seemingly a better short-term safety profile compared to conventional dexamethasone treatment.

Original languageEnglish (US)
Pages (from-to)297-304
Number of pages8
JournalJournal of Perinatology
Volume29
Issue number4
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Betamethasone
Bronchopulmonary Dysplasia
Premature Infants
Dexamethasone
Glucocorticoids
Length of Stay
Newborn Infant
Safety
Therapeutics
Birth Weight
Gestational Age
Weight Gain
Ventilation
Blood Glucose
Oxygen
Pressure

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia : A pilot study. / DeCastro, M.; El-Khoury, N.; Parton, L.; Ballabh, Praveen; LaGamma, E. F.

In: Journal of Perinatology, Vol. 29, No. 4, 2009, p. 297-304.

Research output: Contribution to journalArticle

DeCastro, M. ; El-Khoury, N. ; Parton, L. ; Ballabh, Praveen ; LaGamma, E. F. / Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia : A pilot study. In: Journal of Perinatology. 2009 ; Vol. 29, No. 4. pp. 297-304.
@article{14868332078246c0839b1c67dfb46b51,
title = "Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: A pilot study",
abstract = "Objective: As effects of glucocorticoids differ with respect to preparation, dose and duration, we hypothesized that a postnatal regimen of a low-dose, short-course betamethasone treatment had comparable efficacy and a better safety profile compared to the conventional high-dose, dexamethasone. Study Design: To test our hypothesis, we selected premature neonates with a birth weight ≤1000 g and a gestational age ≤29 weeks who were ventilated >10 postnatal days with an FiO2>0.4 and no ability to wean mechanical support for >3 consecutive days. These neonates either received twice daily dexamethasone 0.25 mg kg-1 per dose intravenously for 3 days tapered to 0.125 mg kg-1 per dose for 4 days (June 1999 to December 2000) or betamethasone 0.125 mg kg-1 per day intramuscularly once per day for 3 days (January 2001 to December 2002). Result: We found a significant reduction in FiO2 after 3 days in both glucocorticoid treatment groups. There were no significant differences between the two treatment groups in the clinical parameters including decrease in FiO2, oxygenation index, mean airway pressure and percent extubation. Duration of ventilation, number of oxygen days and length of hospital stay were comparable in the two groups. Of particular interest, the betamethasone group showed fewer adverse effects, such as poor weight gain and high blood glucose, than the dexamethasone group. Conclusion: A short course of low-dose betamethasone has comparable efficacy and seemingly a better short-term safety profile compared to conventional dexamethasone treatment.",
author = "M. DeCastro and N. El-Khoury and L. Parton and Praveen Ballabh and LaGamma, {E. F.}",
year = "2009",
doi = "10.1038/jp.2008.194",
language = "English (US)",
volume = "29",
pages = "297--304",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia

T2 - A pilot study

AU - DeCastro, M.

AU - El-Khoury, N.

AU - Parton, L.

AU - Ballabh, Praveen

AU - LaGamma, E. F.

PY - 2009

Y1 - 2009

N2 - Objective: As effects of glucocorticoids differ with respect to preparation, dose and duration, we hypothesized that a postnatal regimen of a low-dose, short-course betamethasone treatment had comparable efficacy and a better safety profile compared to the conventional high-dose, dexamethasone. Study Design: To test our hypothesis, we selected premature neonates with a birth weight ≤1000 g and a gestational age ≤29 weeks who were ventilated >10 postnatal days with an FiO2>0.4 and no ability to wean mechanical support for >3 consecutive days. These neonates either received twice daily dexamethasone 0.25 mg kg-1 per dose intravenously for 3 days tapered to 0.125 mg kg-1 per dose for 4 days (June 1999 to December 2000) or betamethasone 0.125 mg kg-1 per day intramuscularly once per day for 3 days (January 2001 to December 2002). Result: We found a significant reduction in FiO2 after 3 days in both glucocorticoid treatment groups. There were no significant differences between the two treatment groups in the clinical parameters including decrease in FiO2, oxygenation index, mean airway pressure and percent extubation. Duration of ventilation, number of oxygen days and length of hospital stay were comparable in the two groups. Of particular interest, the betamethasone group showed fewer adverse effects, such as poor weight gain and high blood glucose, than the dexamethasone group. Conclusion: A short course of low-dose betamethasone has comparable efficacy and seemingly a better short-term safety profile compared to conventional dexamethasone treatment.

AB - Objective: As effects of glucocorticoids differ with respect to preparation, dose and duration, we hypothesized that a postnatal regimen of a low-dose, short-course betamethasone treatment had comparable efficacy and a better safety profile compared to the conventional high-dose, dexamethasone. Study Design: To test our hypothesis, we selected premature neonates with a birth weight ≤1000 g and a gestational age ≤29 weeks who were ventilated >10 postnatal days with an FiO2>0.4 and no ability to wean mechanical support for >3 consecutive days. These neonates either received twice daily dexamethasone 0.25 mg kg-1 per dose intravenously for 3 days tapered to 0.125 mg kg-1 per dose for 4 days (June 1999 to December 2000) or betamethasone 0.125 mg kg-1 per day intramuscularly once per day for 3 days (January 2001 to December 2002). Result: We found a significant reduction in FiO2 after 3 days in both glucocorticoid treatment groups. There were no significant differences between the two treatment groups in the clinical parameters including decrease in FiO2, oxygenation index, mean airway pressure and percent extubation. Duration of ventilation, number of oxygen days and length of hospital stay were comparable in the two groups. Of particular interest, the betamethasone group showed fewer adverse effects, such as poor weight gain and high blood glucose, than the dexamethasone group. Conclusion: A short course of low-dose betamethasone has comparable efficacy and seemingly a better short-term safety profile compared to conventional dexamethasone treatment.

UR - http://www.scopus.com/inward/record.url?scp=63649109906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63649109906&partnerID=8YFLogxK

U2 - 10.1038/jp.2008.194

DO - 10.1038/jp.2008.194

M3 - Article

VL - 29

SP - 297

EP - 304

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 4

ER -